| Dr Emelia Loren Haraguchi, PT, DPT | |
|
2-2488 Kaumualii Hwy, Kalaheo, HI 96741-8311 | |
| (808) 335-5657 | |
| (808) 335-5657 |
| Full Name | Dr Emelia Loren Haraguchi |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 13 Years |
| Location | 2-2488 Kaumualii Hwy, Kalaheo, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841567179 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 38459 (California) | Primary |
| 2251X0800X | Physical Therapist - Orthopedic | 3526 (Hawaii) | Secondary |
| Provider Name | Kauai Independent Rehabilitation Associates Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1508959339 PECOS PAC ID: 7315961596 Enrollment ID: O20060116000378 |
News Archive
Although "multitasking" is a popular buzzword, research shows that only 2% of the population actually multitasks efficiently. Most of us just shift back and forth between different tasks, a process that requires our brains to refocus time and time again - and reduces overall productivity by a whopping 40%.
Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.
Everyone is familiar with urinary stones (kidney stones). The same thing can actually happen in your salivary ducts. These types of stones and strictures occur not nearly as frequently as kidney stones but they still occur quite often. The latest data we have seen showed about 1 in 5,000 patients actually have some type of obstructive salivary duct disorder.
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
› Verified 1 days ago
| Provider Name | Kauai Community Health Alliance |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1659531622 PECOS PAC ID: 7012070774 Enrollment ID: O20090107000415 |
News Archive
Although "multitasking" is a popular buzzword, research shows that only 2% of the population actually multitasks efficiently. Most of us just shift back and forth between different tasks, a process that requires our brains to refocus time and time again - and reduces overall productivity by a whopping 40%.
Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.
Everyone is familiar with urinary stones (kidney stones). The same thing can actually happen in your salivary ducts. These types of stones and strictures occur not nearly as frequently as kidney stones but they still occur quite often. The latest data we have seen showed about 1 in 5,000 patients actually have some type of obstructive salivary duct disorder.
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
› Verified 1 days ago
| Provider Name | Ohana Sports Medicine Kapaa Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1386117927 PECOS PAC ID: 2961741053 Enrollment ID: O20190307001646 |
News Archive
Although "multitasking" is a popular buzzword, research shows that only 2% of the population actually multitasks efficiently. Most of us just shift back and forth between different tasks, a process that requires our brains to refocus time and time again - and reduces overall productivity by a whopping 40%.
Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.
Everyone is familiar with urinary stones (kidney stones). The same thing can actually happen in your salivary ducts. These types of stones and strictures occur not nearly as frequently as kidney stones but they still occur quite often. The latest data we have seen showed about 1 in 5,000 patients actually have some type of obstructive salivary duct disorder.
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
› Verified 1 days ago
| Provider Name | Haraguchi Physical Therapy & Orthopedics Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1033879515 PECOS PAC ID: 2668865155 Enrollment ID: O20220318002063 |
News Archive
Although "multitasking" is a popular buzzword, research shows that only 2% of the population actually multitasks efficiently. Most of us just shift back and forth between different tasks, a process that requires our brains to refocus time and time again - and reduces overall productivity by a whopping 40%.
Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.
Everyone is familiar with urinary stones (kidney stones). The same thing can actually happen in your salivary ducts. These types of stones and strictures occur not nearly as frequently as kidney stones but they still occur quite often. The latest data we have seen showed about 1 in 5,000 patients actually have some type of obstructive salivary duct disorder.
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emelia Loren Haraguchi, PT, DPT Po Box 83, Hanalei, HI 96714-0083 Ph: () - | Dr Emelia Loren Haraguchi, PT, DPT 2-2488 Kaumualii Hwy, Kalaheo, HI 96741-8311 Ph: (808) 335-5657 |
News Archive
Although "multitasking" is a popular buzzword, research shows that only 2% of the population actually multitasks efficiently. Most of us just shift back and forth between different tasks, a process that requires our brains to refocus time and time again - and reduces overall productivity by a whopping 40%.
Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.
Everyone is familiar with urinary stones (kidney stones). The same thing can actually happen in your salivary ducts. These types of stones and strictures occur not nearly as frequently as kidney stones but they still occur quite often. The latest data we have seen showed about 1 in 5,000 patients actually have some type of obstructive salivary duct disorder.
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
› Verified 1 days ago
Paulette Lum, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4845c Puuwai Rd, Kalaheo, HI 96741 Phone: 808-651-2327 | |
Jeshua Spadino, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2-2488 Kaumualii Hwy, Kalaheo, HI 96741 Phone: 808-335-5808 | |
Michelle Pacilio, MPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2-2488 Kaumualii Hwy, Kalaheo, HI 96741 Phone: 808-335-5808 Fax: 808-335-5657 | |
Thomas A Hazelton, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2-2488 Kaumualii Hwy, Kalaheo, HI 96741 Phone: 808-335-5808 Fax: 808-335-5657 | |
Brittany Marie Largo, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2-2488 Kaumualii Hwy, Kalaheo, HI 96741 Phone: 808-320-7159 Fax: 808-335-5657 | |
Ohana Sports Medicine Physical Therapist Medicare: Medicare Enrolled Practice Location: 2-2488 Kaumualii Hwy, Kalaheo, HI 96741 Phone: 808-335-5808 Fax: 808-335-5657 | |
Roberto Castillo, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2-2514 Kaumualii Hwy Ste 211, Kalaheo, HI 96741 Phone: 808-808-4958 Fax: 808-495-8669 |